表紙
市場調查報告書

全球體外診斷(IVD)市場:各技術、產品、實用性、用途、終端用戶、地區 - 成長,趨勢,預測(2018年∼2023年)

In-Vitro Diagnostic Market - Growth, Trends, and Forecasts (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 390830
出版日期 內容資訊 英文 115 Pages
商品交期: 2-3個工作天內
價格
全球體外診斷(IVD)市場:各技術、產品、實用性、用途、終端用戶、地區 - 成長,趨勢,預測(2018年∼2023年) In-Vitro Diagnostic Market - Growth, Trends, and Forecasts (2020 - 2025)
出版日期: 2020年08月01日內容資訊: 英文 115 Pages
簡介

體外診斷(IVD),用多樣的生物檢體做健康狀態的診斷。全球體外診斷(IVD)市場,從調查期間的2018年到2023年5.5%的年複合成長率發展的事預計。

本報告提供全球體外診斷(IVD)市場相關調查,市場概要,各技術、產品、實用性、用途、終端用戶、地區的市場趨勢,市場規模的變化與預測,成長要素、阻礙因素以及市場機會、課題分析,競爭情形,主要企業的簡介等系統性資訊。

目錄

第1章 簡介

  • 市場定義

第2章 調查方法

第3章 摘要整理

第4章 主要影響要素

第5章 市場概要

  • 目前市場方案
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第6章 成長要素,阻礙因素,市場機會,課題分析(DROC)

  • 成長要素
    • 慢性疾病及感染性疾病的高罹患率
    • POC診斷的利用的增加
    • 先進技術
    • 私立醫院及獨立檢驗機關的增加
  • 阻礙因素
    • 嚴格的法規
    • 繁雜的償付手續
    • 開發中國家醫院和研究所的有限預算
  • 市場機會
  • 主要課題

第7章 全球體外診斷(IVD)市場:各市場區隔

  • 各技術
    • 免疫化學
    • POC診斷
    • 分子診斷
    • 血液學
    • 組織診斷
    • 微生物學
    • 血糖自我檢測
    • 其他
  • 各產品
    • 設備
    • 試劑
    • 資料管理系統
  • 各實用性
    • 拋棄式
    • 可重複使用
  • 各用途
    • 感染疾病
    • 糖尿病
    • 癌症/腫瘤學
    • 心臟病
    • 自體免疫疾病
    • 腎臟病
    • 藥物檢驗
    • HIV/AIDS
    • 其他
  • 各終端用戶
    • 研究所
    • 醫院
    • 學術機構
    • POC檢驗
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第8章 競爭情形

  • 合併、收購分析
  • 協定、聯盟、合作
  • 新產品的銷售

第9章 主要企業的簡介

  • Biomerieux
  • Danaher Corporation
  • Roche Diagnostics
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Abbott Laboratories
  • Bayer AG
  • Arkray, Inc.
  • Sysmex Corporation
  • Johnson & Johnson
  • Siemens AG

第10章 市場未來展望

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 49602

Global In-Vitro Diagnostic market is expected to grow with a CAGR of 4.81% over the forecast period. The growth of the global IVD market can be attributed to the high prevalence of chronic and infectious diseases. Chronic diseases are a growing global challenge, and according to WHO estimates, account for approximately 60% of all deaths, worldwide. The current market is also growing due to the use of advanced technologies in the IVD market. There has been a paradigm shift from traditional diagnostics to a new generation diagnostics that work at the gene level. This was made possible by the inclusion of advanced technologies, such as genetic testing, molecular diagnostics, polymerase chain reaction (PCR) and next-generation sequencing (NGS).

Key Market Trends

Reagents are Expected to hold Largest Market Share in the Product Segment

In the product segment of the In-Vitro Diagnostic market, the reagent is believed to have the largest market size and is expected to witness a CAGR of 4.8% in the forecast period.

The reagent segment of the market studied includes chemical, biological, or immunological components, solutions, or preparations intended by the manufacturer to be used during the in-vitro diagnosis process. Given the high cost of many diagnostic platforms, it is common for manufacturers to lease equipment instead of selling technology outright to end users. In these arrangements, the lease is tied to contracts to purchase associated reagents or assays for the equipment over the life of the contract. Many diagnostic companies have in excess of 75% of sales from consumables such as assays and reagents, and such agreements guarantee the generation of cyclic revenues associated with the sale of reagents and other consumables.

Many developing countries have established local immunoassay reagent programs to manufacture low-cost, high-quality immunoassay reagents. Kits from these projects are now beginning to become available and are likely to fuel the market expansion.

North America Dominates the Market and is Expected to continue its Dominance in the Forecast Period

North America currently dominates the market for In-Vitro Diagnostic and is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future owing to the well-established healthcare industry and rising prevalence of the chronic diseases in the region. The United States holds the majority of the market in the North America region; this is due to the rising healthcare expenditure, along with rapid adoption of point-of-care testing.

Competitive Landscape

The In-Vitro Diagnostic market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancement and product innovation, mid-size to smaller companies are increasing their market presence by introducing new products at lesser prices. Companies like Thermo Fischer Scientific Inc., Abbott Laboratories, Siemens Healthcare GmbH and F. Hoffmann-La Roche AG. holds the substantial market share in the In-Vitro Diagnostic market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 High Prevalence of Chronic Diseases
    • 4.2.2 Increasing Use of Point-of-care (POC) Diagnostics
    • 4.2.3 Advanced Technologies in In-vitro Diagnostic Products
    • 4.2.4 Increasing Awareness and Acceptance of Personalized Medicine and Companion Diagnostics
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulations Regarding Product Approvals
    • 4.3.2 Cumbersome Reimbursement Procedures
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Test Type
    • 5.1.1 Clinical Chemistry
    • 5.1.2 Molecular Diagnostics
    • 5.1.3 Immuno Diagnostics
    • 5.1.4 Haematology
    • 5.1.5 Other Types
  • 5.2 By Product
    • 5.2.1 Instruments
    • 5.2.2 Reagents
    • 5.2.3 Other Products
  • 5.3 By Usability
    • 5.3.1 Disposable IVD Devices
    • 5.3.2 Reusable IVD Devices
  • 5.4 By Application
    • 5.4.1 Infectious Disease
    • 5.4.2 Diabetes
    • 5.4.3 Cancer/Oncology
    • 5.4.4 Cardiology
    • 5.4.5 Autoimmune Disease
    • 5.4.6 Nephrology
    • 5.4.7 Other Applications
  • 5.5 By End Users
    • 5.5.1 Diagnostic Laboratories
    • 5.5.2 Hospitals & Clinics
    • 5.5.3 Other End Users
  • 5.6 Geography
    • 5.6.1 North America
      • 5.6.1.1 United States
      • 5.6.1.2 Canada
      • 5.6.1.3 Mexico
    • 5.6.2 Europe
      • 5.6.2.1 Germany
      • 5.6.2.2 United Kingdom
      • 5.6.2.3 France
      • 5.6.2.4 Italy
      • 5.6.2.5 Spain
      • 5.6.2.6 Rest of Europe
    • 5.6.3 Asia-Pacific
      • 5.6.3.1 China
      • 5.6.3.2 Japan
      • 5.6.3.3 India
      • 5.6.3.4 Australia
      • 5.6.3.5 South Korea
      • 5.6.3.6 Rest of Asia-Pacific
    • 5.6.4 Middle-East and Africa
      • 5.6.4.1 GCC
      • 5.6.4.2 South Africa
      • 5.6.4.3 Rest of Middle-East and Africa
    • 5.6.5 South America
      • 5.6.5.1 Brazil
      • 5.6.5.2 Argentina
      • 5.6.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 BioMerieux SA
    • 6.1.2 Danaher Corporation
    • 6.1.3 F. Hoffmann-La Roche Ltd
    • 6.1.4 Becton, Dickinson and Company
    • 6.1.5 Bio-Rad Laboratories, Inc.
    • 6.1.6 Abbott Laboratories
    • 6.1.7 Arkray Inc.
    • 6.1.8 Sysmex Corporation
    • 6.1.9 Ortho Clinical Diagnostics
    • 6.1.10 Siemens Healthcare GmbH
    • 6.1.11 Thermo Fischer Scientific Inc

7 MARKET OPPORTUNITIES AND FUTURE TRENDS